Condition: Atopic Dermatitis (AD) · Sponsor: Zai Lab (Shanghai) Co., Ltd.
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)
This description comes directly from the study's public registry record.
ZaiLab Medical Director · +86 021-61632588 · ZaiLab_1503-001_StudyTeam@zailaboratory.com
Always discuss trial participation with your own doctor first.
| ZaiLab Site 18001 | Auckland, Auckland, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07235384